Optimization and prediction of drug release from matrix tablets using response surface methodology and near infrared chemical imaging

Pharmaceutical Development and Technology

Volumn 17, Issue 4, 2012, Pages 398-406

  Bagchi, Saumitra ^a   Li, Weiyong ^b   Plakogiannis, Fotios ^a  

^a LONG ISLAND UNIVERSITY   (United States)

^b Asta Tech Inc   (United States)

Author keywords

Matrix tablet; Niacin; NIR CI; Partial least square analysis; Response surface methodology

Indexed keywords

ETHYL CELLULOSE; LACTOSE; MACROGOL; NICOTINIC ACID;

ANALYTIC METHOD; ARTICLE; DRUG DIFFUSION; DRUG FORMULATION; DRUG RELEASE; NEAR INFRARED CHEMICAL IMAGING; PRIORITY JOURNAL; RESPONSE SURFACE METHOD; STATISTICAL ANALYSIS; TABLET;

CELLULOSE; DELAYED-ACTION PREPARATIONS; LACTOSE; LEAST-SQUARES ANALYSIS; NIACIN; POLYETHYLENE GLYCOLS; SPECTROSCOPY, NEAR-INFRARED; VITAMIN B COMPLEX;

EID: 84862279299     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2010.546405     Document Type: Article

References (24)

1. Colombo P, Gazzaniga A, Caramella C, Conte U, La Manna A.In vitro programmable zero-order release drug delivery system. Acta Pharm Technol 1987;33:15-20.
2. Konard R, Christ A, Zessin G, Cobet U.The use of ultrasound and penetrometer to characterize the advancement of swelling and eroding fronts in HPMC matrices. Int J Pharm 1998;163:123-131.
3. Thomas N, Windle AH.Transport of methanol in poly(methylmethacrylate). Polymer 1978;19:255-265.
4. Gao P, Meury H.Swelling of hydroxypropyl methylcellulose matrix tablets.1.Characterization of swelling using a novel optical imaging method.J Pharm Sci 1996;52:1145-1149.
5. Moussa IS, Lenaerts V, Cartilier LH.Image analysis studies of water transport and dimensional changes occurring in the early stages of hydration in cross-linked amylose matrices. J Controlled Release 1998;52:63-70.
6. Weisenberg LA, Koenig JL.An NMR imaging study of methanol desorption from partially swollen PMMA rods. Macromolecules 1990;23:2454-2459.
7. Rajabi-Siahboomi AR, Bowtell RW, Mansfield P, Henderson A, Davies MC, Melia CD.Structure and behavior in hydrophilic matrix sustained release dosage forms: 2.NMR-imaging studies of dimensional changes in the gel layer and core of HPMC tablets undergoing hydration. J Controlled Release 1994;31:121-128.
8. Mills PJ, Palmstrom CJ, Kramer EJ.Concentration profiles of non- Fickian diffusants in glassy polymers by Rutherford backscattering spectrometry. J Mater Sci 1986;21:1479-1486.
9. Li W, Woldu A, Araba L, Winstead D.Determination of water penetration and drug concentration profiles in HPMC-based matrix tablets by near infrared chemical imaging. J Pharm Sci 2010 (in press).
10. Carsten R, Skibsted E, Rasmus B.Near-Infrared chemical imaging (NIR-CI) on pharmaceutical solid dosage forms-Comparing common calibration approaches. Journal of Pharmaceutical and Biomedical Analysis 2008;48:554-561.
11. Li W, Woldu A, Kelly R, McCool J, Bruce R, Rasmussen H, Cunningham J, Winstead D.Measurement of drug agglomerates in powder blending simulation samples by near infrared chemical imaging. Int J Pharm 2008;350:369-373.
12. Lee E, Huang WX, Chen P, Lewis EN, Vivlecchia RV.High throughput analysis of pharmaceutical tablet content uniformity by near-infrared chemical imaging. Spectroscopy 2006;22.
13. Takayama K, Nagai T.Novel computer optimization methodology for pharmaceutical formulations investigated by using sustained-release granules of indomethacin. Chem Pharm Bull 1989;37:160-167.
14. Singh SK, Dodge J, Durrani MJ, Khan M.Factorial design in the feasibility of producing Microcel MC 101 pellets by extrusion spheronization. Int J Pharm 1995;115:53-60.
15. Bouckaert S, Massart DL, Massart B, Rremon JP.Optimization of a granulation procedure for a hydrophilic matrix tablet design. Drug Dev Ind Pharm 1996;22:321-327.
16. Huang YB, Tsai YH, Yang WC, Chang JS, Wu PC, Takayama K.Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation. Eur J Pharm Biopharm 2004a; 58:607-614.
17. Huanga Y, Tsaia Y, Leea S, Changa J, Wu P.Optimization of pH-independent release of nicardipine hydrochloride extendedrelease matrix tablets using response surface methodology. Int J Pharm 2005;289:87-95.
18. Brown W, Knopp RH.The use of niacin. Journal of Clinical Lipidology 2009;3:65-69.
19. Guyton JR, Simmons PD.Flushing and other dermatologic adverse events associated with extended-release niacin therapy. Journal of Clinical Lipidology 2009;3:101-108.
20. Pieper JA.Understanding niacin formulations. Am J Manag Care 2002;8(12 Suppl):308-314.
21. Pieper JA.Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. Am J Health Syst Pharm 2003;1:9-14.
22. McKenney JM, Proctor JD, Harris S, Chinchili VM.A comparison of the efficacy and toxic effects of sustained- vs immediaterelease niacin in hypercholesterolemic patients. JAMA 1994;2: 672-677.
23. Knopp RH.Evaluating niacin in its various forms. Am J Cardiol 2000;21:51-56.
24. Nazzal S, El-Malah Y, Khanfar NM.D-Optimal Mixture Design: Optimization of Ternary Matrix Blends for Controlled Zero-Order Drug Release from Oral Dosage Forms. Drug Dev Ind Pharm 2006;32:1207-1218.